Massachusetts-based dry-powder specialist Pulmatrix welcomed successful early-stage results for its bronchodilator treatment for chronic obstructive pulmonary disorder, which makes use of its novel lung delivery system iSPERSE.
Boehringer Ingelheim has won over European regulators with its latest COPD therapy, following a favorable FDA panel vote that set the stage for U.S. approval and entrance into a huge but crowded market.
Novartis is launching the expected blockbuster into a rapidly expanding but increasingly competitive market as established players and newcomers vie for their piece of the action.
GlaxoSmithKline and Theravance have nailed down a solid majority of FDA panel votes in favor of marketing their new COPD therapy Anoro Ellipta. The outside experts voted 11 to 2 this afternoon to endorse the therapy, opening the door to the first of several new drug that will likely wind up duking it out in a tough fight for market share.
Over the weekend some of the world's largest drug developers rolled out new data on their late-stage COPD drugs, staying upbeat despite a growing sense among some analysts that many of these new drugs will find it hard to offer much in the way of a significant improvement for patients.
The delay could interfere with their plans to compete against rival drugs that could get to market first.
3M licensed its dry powder drug delivery device for asthma and chronic obstructive pulmonary disease to Adamis for an undisclosed amount, granting the smaller company worldwide rights to bolster its own line of delivery devices.
Few productivity metrics in biopharma measure up to the annual rate of new drug approvals. So now that the FDA has come through with only 13 novel approvals in the first half of the year, well off the pace of 39 new approvals in 2012, there's some handwringing going on.
Swiss pharma giant Novartis has earned an endorsement from the European Committee for Medicinal Products for Human Use for it once-daily Ultibro Breezhaler to treat chronic obstructive pulmonary disease.
Elan's shareholders rejected a string of CEO Kelly Martin's deals today, but did green-light a share repurchase pact--which the biotech says will put the hex on Royalty Pharma's hostile $8 billion offer for the company. The hostile bid, though, was already being reconsidered at the end of last week, when Elan's board decided to formally put the company on the auction block, inviting Royalty to take a seat at the bidding table.